Cargando…

Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience

Lorlatinib is the only targeted therapy approved in Canada to treat patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) whose tumor has progressed despite treatment with second-generation ALK tyrosine kinase inhibitor (TKI), a patient population with high unmet...

Descripción completa

Detalles Bibliográficos
Autores principales: Rupp, Martin, Fanton-Aita, Fiorella, Snow, Stephanie, Wheatley-Price, Paul, Melosky, Barbara, Juergens, Rosalyn A., Chu, Quincy, Blais, Normand, Banerji, Shantanu, Ng, Ryan, Khoudigian, Shoghag, Sharma, Arushi, On, Phu Vinh, Liu, Geoffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377946/
https://www.ncbi.nlm.nih.gov/pubmed/37504341
http://dx.doi.org/10.3390/curroncol30070481
_version_ 1785079643843330048
author Rupp, Martin
Fanton-Aita, Fiorella
Snow, Stephanie
Wheatley-Price, Paul
Melosky, Barbara
Juergens, Rosalyn A.
Chu, Quincy
Blais, Normand
Banerji, Shantanu
Ng, Ryan
Khoudigian, Shoghag
Sharma, Arushi
On, Phu Vinh
Liu, Geoffrey
author_facet Rupp, Martin
Fanton-Aita, Fiorella
Snow, Stephanie
Wheatley-Price, Paul
Melosky, Barbara
Juergens, Rosalyn A.
Chu, Quincy
Blais, Normand
Banerji, Shantanu
Ng, Ryan
Khoudigian, Shoghag
Sharma, Arushi
On, Phu Vinh
Liu, Geoffrey
author_sort Rupp, Martin
collection PubMed
description Lorlatinib is the only targeted therapy approved in Canada to treat patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) whose tumor has progressed despite treatment with second-generation ALK tyrosine kinase inhibitor (TKI), a patient population with high unmet need and lack of publicly reimbursed targeted treatments in Canada. We prospectively examined the real-world effectiveness and impact of lorlatinib on quality-of-life in 59 lorlatinib-treated patients, characterized as: median age of 62.0 years; 47.5% were female; 32.2% had central nervous system metastases; 50.8% had 2+ prior ALK TKI lines; and alectinib was the most common ALK TKI (72.9%) administered before lorlatinib, including 44.1% who received first-line alectinib. With a median follow-up of 15.3 months (IQR: 6.2–19.2), median time-to-treatment discontinuation of lorlatinib was 15.3 months (95% CI: 7.9–not reached), with 54.2% (95% CI: 40.8–65.9%) of patients without treatment discontinuation at 12 months. At baseline, the mean health utility score (HUS) was 0.744 (SD: 0.200). At 3 months, patients receiving lorlatinib demonstrated a 0.069 (95% CI: 0.020–0.118; p = 0.007) average HUS increase over baseline; HUS was maintained at 6 and 12 months. Thus, patients with ALK-positive NSCLC post second-generation ALK TKI remained on lorlatinib for a meaningful duration of time while their quality-of-life was preserved.
format Online
Article
Text
id pubmed-10377946
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103779462023-07-29 Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience Rupp, Martin Fanton-Aita, Fiorella Snow, Stephanie Wheatley-Price, Paul Melosky, Barbara Juergens, Rosalyn A. Chu, Quincy Blais, Normand Banerji, Shantanu Ng, Ryan Khoudigian, Shoghag Sharma, Arushi On, Phu Vinh Liu, Geoffrey Curr Oncol Article Lorlatinib is the only targeted therapy approved in Canada to treat patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) whose tumor has progressed despite treatment with second-generation ALK tyrosine kinase inhibitor (TKI), a patient population with high unmet need and lack of publicly reimbursed targeted treatments in Canada. We prospectively examined the real-world effectiveness and impact of lorlatinib on quality-of-life in 59 lorlatinib-treated patients, characterized as: median age of 62.0 years; 47.5% were female; 32.2% had central nervous system metastases; 50.8% had 2+ prior ALK TKI lines; and alectinib was the most common ALK TKI (72.9%) administered before lorlatinib, including 44.1% who received first-line alectinib. With a median follow-up of 15.3 months (IQR: 6.2–19.2), median time-to-treatment discontinuation of lorlatinib was 15.3 months (95% CI: 7.9–not reached), with 54.2% (95% CI: 40.8–65.9%) of patients without treatment discontinuation at 12 months. At baseline, the mean health utility score (HUS) was 0.744 (SD: 0.200). At 3 months, patients receiving lorlatinib demonstrated a 0.069 (95% CI: 0.020–0.118; p = 0.007) average HUS increase over baseline; HUS was maintained at 6 and 12 months. Thus, patients with ALK-positive NSCLC post second-generation ALK TKI remained on lorlatinib for a meaningful duration of time while their quality-of-life was preserved. MDPI 2023-07-08 /pmc/articles/PMC10377946/ /pubmed/37504341 http://dx.doi.org/10.3390/curroncol30070481 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rupp, Martin
Fanton-Aita, Fiorella
Snow, Stephanie
Wheatley-Price, Paul
Melosky, Barbara
Juergens, Rosalyn A.
Chu, Quincy
Blais, Normand
Banerji, Shantanu
Ng, Ryan
Khoudigian, Shoghag
Sharma, Arushi
On, Phu Vinh
Liu, Geoffrey
Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience
title Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience
title_full Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience
title_fullStr Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience
title_full_unstemmed Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience
title_short Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience
title_sort lorlatinib effectiveness and quality-of-life in patients with alk-positive nsclc who had failed second-generation alk inhibitors: canadian real-world experience
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377946/
https://www.ncbi.nlm.nih.gov/pubmed/37504341
http://dx.doi.org/10.3390/curroncol30070481
work_keys_str_mv AT ruppmartin lorlatinibeffectivenessandqualityoflifeinpatientswithalkpositivensclcwhohadfailedsecondgenerationalkinhibitorscanadianrealworldexperience
AT fantonaitafiorella lorlatinibeffectivenessandqualityoflifeinpatientswithalkpositivensclcwhohadfailedsecondgenerationalkinhibitorscanadianrealworldexperience
AT snowstephanie lorlatinibeffectivenessandqualityoflifeinpatientswithalkpositivensclcwhohadfailedsecondgenerationalkinhibitorscanadianrealworldexperience
AT wheatleypricepaul lorlatinibeffectivenessandqualityoflifeinpatientswithalkpositivensclcwhohadfailedsecondgenerationalkinhibitorscanadianrealworldexperience
AT meloskybarbara lorlatinibeffectivenessandqualityoflifeinpatientswithalkpositivensclcwhohadfailedsecondgenerationalkinhibitorscanadianrealworldexperience
AT juergensrosalyna lorlatinibeffectivenessandqualityoflifeinpatientswithalkpositivensclcwhohadfailedsecondgenerationalkinhibitorscanadianrealworldexperience
AT chuquincy lorlatinibeffectivenessandqualityoflifeinpatientswithalkpositivensclcwhohadfailedsecondgenerationalkinhibitorscanadianrealworldexperience
AT blaisnormand lorlatinibeffectivenessandqualityoflifeinpatientswithalkpositivensclcwhohadfailedsecondgenerationalkinhibitorscanadianrealworldexperience
AT banerjishantanu lorlatinibeffectivenessandqualityoflifeinpatientswithalkpositivensclcwhohadfailedsecondgenerationalkinhibitorscanadianrealworldexperience
AT ngryan lorlatinibeffectivenessandqualityoflifeinpatientswithalkpositivensclcwhohadfailedsecondgenerationalkinhibitorscanadianrealworldexperience
AT khoudigianshoghag lorlatinibeffectivenessandqualityoflifeinpatientswithalkpositivensclcwhohadfailedsecondgenerationalkinhibitorscanadianrealworldexperience
AT sharmaarushi lorlatinibeffectivenessandqualityoflifeinpatientswithalkpositivensclcwhohadfailedsecondgenerationalkinhibitorscanadianrealworldexperience
AT onphuvinh lorlatinibeffectivenessandqualityoflifeinpatientswithalkpositivensclcwhohadfailedsecondgenerationalkinhibitorscanadianrealworldexperience
AT liugeoffrey lorlatinibeffectivenessandqualityoflifeinpatientswithalkpositivensclcwhohadfailedsecondgenerationalkinhibitorscanadianrealworldexperience